Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Vaccine Developers ‘Chlamp’ Down on Chlamydia

Chlamydia trachomatis are Gram-negative bacteria characterized by an intracellular development using the host’s own ATP to survive and proliferate. It is responsible for ocular, genital and respiratory infections and is the most common sexually transmitted disease of bacterial origin. C. trachomatis native antigens are direct targets for the immune system and could help in generating T cell and antibody responses. Using high-throughput proteomic screening, Dr. Jessica Baker Flechtner and her team from Genocea Biosciences and Harvard Medical School identified 13 antigens derived from C. trachomatis capable of inducing either CD4+ or CD8+ T cell responses in experimentally infected mice. Two of these antigens were assessed further as potential vaccine candidates. In combination with the adjuvant AbISCO-100, strong and long-lasting protections were seen against vaginal challenges in mice with the generation of protein-specific CD4+ Th1 and CD8+ cytotoxic T cell responses. The role of T cells was further emphasized by the efficiency of adoptive T cell transfer in achieving the same feat and the absence of a humoral response. Their findings, presented in the June 2012 issue of Vaccine, underlined the need to identify and characterize other potential antigenic candidates to accelerate development and release of a prophylactic and/or therapeutic C. trachomatis vaccine.

Enzo Life Sciences enables scientists to develop such vaccines against a variety of micro-organisms by offering a comprehensive list of antigens for use in ELISA/ELISPOT as positive controls, as well as toxins for cytotoxicity studies, some of which are described below:

 

Related Products

C. trachomatis native antigen 

Cell lysate ideal for use as a broad positive control
From Chlamydia trachomatis, serotype LGV2 strain 434. Inactivated by heat treatment and 0.05% Triton X-100., ELISA, Positive control | Print as PDF
 
ALX-630-124-1000 1 ml 629.00 USD
Do you need bulk/larger quantities?
 

Adenovirus type 5 hexon protein 

From adenovirus type 5., ≥95% (SDS-PAGE), ELISA, Antibody capture, Positive control | Print as PDF
 
ALX-630-120-0100 100 µg 278.00 USD
Do you need bulk/larger quantities?
 

Adenovirus type 40 antigen 

From adenovirus type 40. Inactivated by 2 hours at 54°C., ≥99%, ELISA, Antibody capture, Immunogen, LINE assay | Print as PDF
 
ALX-630-121-0100 100 µg 334.00 USD
Do you need bulk/larger quantities?
 

Astrovirus type 1 antigen 

Concentrated source of Astrovirus particles and proteins
From astrovirus type 1, strain A88/2 Newcastle. Inactivated by b-propiolactone 0.1% and 4 hours at 32°C., ELISA, Positive control | Print as PDF
 
ALX-630-122-0200 200 µl 629.00 USD
Do you need bulk/larger quantities?
 

Bordetella pertussis toxin 

High purity toxin with minimal lot-to-lot variation
70323-44-3, From Bordetella pertussis, strain NCTC 10739., ≥98%, ELISA, Antibody capture, Cytotoxicity studies, LINE assay | Print as PDF
 
BML-G101-0050 50 µg 299.00 USD
Do you need bulk/larger quantities?
 

Pertussis toxin (Bordetella pertussis) 

Ultra-pure pertussis toxin delivering optimal antigenicity
70323-44-3, From Bordetella pertussis, strain 165., ≥99% | Print as PDF
 
BML-G100-0050 50 µg 405.00 USD
Do you need bulk/larger quantities?
 

Bordetella pertussis FHA 

From Bordetella pertussis, strain NCTC 10739., ≥98% (SDS-PAGE), ELISA, Antibody capture, LINE assay | Print as PDF
 
ALX-630-123-0100 100 µg 304.00 USD
Do you need bulk/larger quantities?
 

C. difficile toxin A 

From Clostridium difficile, strain VPI10463., ≥95% (SDS-PAGE), ELISA, Antibody capture, Cytotoxicity studies, LINE assay | Print as PDF
 
BML-G140-0050 50 µg 331.00 USD
Do you need bulk/larger quantities?
 

C. difficile toxin B 

From Clostridium difficile, strain VPI10463., ≥95% (SDS-PAGE), ELISA, Antibody capture, Cytotoxicity studies, LINE assay | Print as PDF
 
BML-G150-0050 50 µg 792.00 USD
Do you need bulk/larger quantities?
 

C. difficile toxoid A 

From Clostridium difficile, strain VPI10463. Inactivated by formaldehyde., ≥95% (SDS-PAGE), ELISA, Antibody capture, Cytotoxicity studies, Immunogen, LINE assay | Print as PDF
 
BML-G145-0050 50 µg 365.00 USD
Do you need bulk/larger quantities?
 

C. difficile toxoid B 

From Clostridium difficile, strain VPI10463. Inactivated by formaldehyde., ≥95% (SDS-PAGE), ELISA, Antibody capture, Cytotoxicity studies, Immunogen, LINE assay | Print as PDF
 
BML-G155-0050 50 µg 792.00 USD
Do you need bulk/larger quantities?
 

Cholera toxin (Vibrio cholerae), (azide free) 

G protein activator
9012-63-9, From Vibrio cholerae. | Print as PDF
 
BML-G117-0001 1 mg 199.00 USD
Do you need bulk/larger quantities?
 

Cholera toxin B subunit (Vibrio cholerae) 

G protein activator
131096-89-4, From Vibrio cholerae. | Print as PDF
 
BML-G125-0001 1 mg Inquire for pricing
Do you need bulk/larger quantities?
 

CMV native antigen 

From cytomegalovirus, strain AD169. Inactivated by 0.2% Triton X-100., ≥95%, ELISA, Antibody capture, Positive control | Print as PDF
 
ALX-630-125-0100 100 µg 447.00 USD
Do you need bulk/larger quantities?
 

HSV-1 native antigen 

From herpes simplex virus type 1. Inactivated by 0.1% Triton X-100., ≥80%, ELISA, Antibody capture, Positive control | Print as PDF
 
ALX-630-126-0200 200 µl 479.00 USD
Do you need bulk/larger quantities?
 

HSV-2 native antigen 

From herpes simplex virus type 2, strain G. Inactivated by 0.1% Triton X-100., ≥80%, ELISA, Antibody capture, Positive control | Print as PDF
 
ALX-630-127-0200 200 µl 480.00 USD
Do you need bulk/larger quantities?
 

N. gonorrhoeae native antigen 

Bacterial lysate ideal for use as a broad positive control
From Neisseria gonorrhoeae, strain ATCC 19424. Inactivated by 3 hours at 56°C., ≥99%, ELISA, Antibody capture, Cytotoxicity studies, Immunogen, LINE assay | Print as PDF
 
ALX-630-129-1000 1 ml 579.00 USD
Do you need bulk/larger quantities?
 

T. vaginalis native antigen 

Cell lysate ideal for use as a broad positive control
From Trichomonas vaginalis, strain C-1:NIH. Inactivated by freezing/thawing in water., ≥99%, ELISA, Antibody capture, Cytotoxicity studies, Immunogen, LINE assay | Print as PDF
 
ALX-630-130-1000 1 ml 580.00 USD
Do you need bulk/larger quantities?
 

References:

  • Picard MD, et al. High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge. Vaccine (2012) 30: 4387-4393.

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2019 Enzo Life Sciences, Inc.,